Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1

Fig. 4

MicroRNA-195 and drugs effect in UACC-62 melanoma cells. (a-b) Cell viability rate was calculated based on the proliferation index ratio (%) of treated cells/not treated cells (control). Increasing doses of cisplatin (2.5, 5.0, and 10.0 ΌM) and temozolomide (50, 250, and 450 ΌM) were tested. (c-d) FlowJo Cytometry Analysis software was used for hypodiploid cell quantification after propidium iodide staining. Cells were treated with 2.5 and 5.0 ΌM cisplatin and 50 and 250 ΌM temozolomide drugs. (e-f) Apoptosis index based on caspase 3/7 activity was measured in a luminometer. All results showed that miR-195 exerts a small effect in UACC-62 melanoma cells sensitization to cisplatin and temozolomide treatments. All experimental data were obtained 24 h after miRNA-control/miR-195 (10 nM) transfection plus 48 h of drug exposure (total time 72 h). Statistical analysis was carried out using ANOVA with multiple comparison test and are reported as means ± SD. Representative data of at least three independent experiments are reported. NS: non-significant; **P ≀ 0.01;***P ≀ 0.001; **** P ≀ 0.0001

Back to article page